Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(18/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(18/week)
News
United States
(572/week)
Manufacturing
(420/week)
Energy
(315/week)
Technology
(459/week)
Other Manufacturing
(342/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Ramucirumab
May 29, 2020
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Feb 26, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Jan 25, 2020
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)
Dec 13, 2019
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Oct 07, 2019
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
May 15, 2019
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
May 13, 2019
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
Feb 25, 2019
FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Jan 18, 2019
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
Jan 01, 2019
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
Oct 21, 2018
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Oct 08, 2018
Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care
Jun 21, 2018
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018
May 16, 2018
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
May 09, 2018
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Apr 20, 2018
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Apr 04, 2018
Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint
Dec 08, 2017
Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
Oct 16, 2017
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
Sep 10, 2017
Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
Page 1
››
Latest News
May 2, 2024
Reliant Home Run Derby with Dallas Cowboys Scores $145,000 to North Texas Nonprofits
May 2, 2024
Compass Minerals Announces Conference Call to Discuss Second-Quarter Fiscal 2024 Results
May 2, 2024
Columbia Sportswear Company Hires Michael Minter as SOREL, VP Brand
May 2, 2024
Hess Midstream LP to Participate in Investor Conferences
May 2, 2024
Valaris Reports First Quarter 2024 Results
May 2, 2024
Materion Corporation Reports First Quarter 2024 Financial Results
May 2, 2024
Cactus Announces First Quarter 2024 Results
May 2, 2024
EnerSys Announces Date of Fourth Quarter and Full Year Fiscal 2024 Financial Results Release and Conference...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events